Related Experiment Video
Updated: Jul 15, 2026

Microscopy-based Assays for High-throughput Screening of Host Factors Involved in Brucella Infection of Hela Cells
Published on: August 5, 2016
Tigecycline: its potential for treatment of brucellosis
Murat Dizbay1, Selcuk Kilic, Kenan Hizel
1Department of Clinical Microbiology and Infectious Diseases, Gazi University School of Medicine, Ankara, Turkey. muratdizbay@gazi.edu.tr
Abstract:
The in vitro efficacy and synergistic activity of tigecycline in comparison with other antimicrobials used in brucellosis, were tested for 16 Brucella melitensis strains by the E-test method. Tigecycline had the lowest minimal inhibitory concentration levels, and rifampin the highest, in the study. Tigecycline also provided the better synergistic activity compared to doxycycline according to the fractional inhibitory concentration index. The results of this in vitro study suggest tigecycline as a therapeutic alternative for brucellosis. These observations need to be supported with clinical studies.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antibiotic Selection
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Inhibitors of Bacterial DNA Synthesis
